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Abstract Our group has shown that 1-year smoking
cessation persisted or increased airway inflammation in
chronic obstructive pulmonary disease (COPD). We com-
pared adenosine and adenosine receptor (AR) expression in
COPD and asymptomatic smokers (AS) before and after
1-year smoking cessation. Sputum cytospins and bronchial
biopsies of (ex)smoking COPD patients and AS were
studied for A1R, A2AR, A2BR, and A3R expression.
Adenosine and inflammatory mediators were measured in
sputum supernatants. At baseline, COPD patients had lower
levels of adenosine and higher levels of vascular endothe-
lial growth factor in sputum than AS. Smoking cessation
induced significantly different effects in COPD than in AS,
i.e. an increase in percentages of A3R expressing neutro-
phils and A1R expressing macrophages in COPD as
increase in adenosine and monocyte chemoattractant pro-
tein-1 levels in sputum. Adenosine-related effector mecha-
nisms may contribute to the persistence and progression of
airway inflammation in COPD following 1-year smoking
cessation.
Keywords Adenosine . Adenosine receptors . COPD .
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease
caused mainly by smoking and it is characterized by
chronic airflow limitation and a range of pathological
changes in the lung [1]. It is known that smoking cessation
stops the accelerated lung function decline present in
COPD [2, 3]. We found that smoking cessation improves
both direct (methacholine) and indirect (adenosine 5′-
monophosphate, AMP) airway hyperresponsiveness (AHR)
after 1-year smoking cessation [4]. Interestingly, improve-
ment of AHR was not associated with changes in lung
function or sputum inflammation. Our previous paper
showed that COPD patients who successfully ceased
smoking for 1-year, overall airway inflammation persisted
in bronchial biopsies, while the number of neutrophils,
lymphocytes, interleukin (IL)-8, and eosinophil-cationic-
protein levels significantly increased in sputum. In addition,
no significant changes in vascular adhesion molecules (i.e.
P-selectin, E-selectin, intercellular antigen-1 (ICAM-1) or
vascular cell adhesion molecule (VCAM)) were found with
smoking cessation in COPD patients also suggesting an
ongoing inflammatory process in the airways. In asymp-
tomatic smokers who successfully quitted smoking, some
inflammatory markers (e.g. sputum macrophages, eosino-
phils, and IL-8) significantly decreased while others did not
change [5]. This indicates that factors other than inflam-
matory cells or measured mediators likely induced the
observed improvement in AHR.
Adenosine has been suggested to play a role in COPD
[6]. Patients with COPD are significantly more responsive
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to AMP than healthy smoking volunteers [7, 8] and
smokers have significantly increased concentrations of
adenosine in the airway lining fluid [9]. Recently, a first
report on the presence of adenosine receptors in lung
parenchyma showed an enhanced density and decreased
affinity of the adenosine receptors in subjects with COPD
compared with control smokers [10]. Adenosine is a purine
nucleoside that is released during tissue hypoxia and
inflammation. It has both pro- and anti-inflammatory fea-
tures, which are mediated by four different G-protein-coupled
receptors, A1 (Gi coupled), A2A (Gs coupled), A2B (Gs and
Gq11 coupled), and A3 (Gs and Gq11 coupled). Activation of
adenosine receptors (AR) can have different effects, depend-
ing on the type of G protein that is involved and the cell type
[6]. Activation of Gi-protein-coupled receptors decreases
adenylyl cyclase activity and cAMP levels whereas activa-
tion of Gs coupled receptors increases cAMP levels [11].
With respect to the cell types involved, activation of A1R on
neutrophils promotes adherence to endothelial cells and
chemotaxis, indicating a pro-inflammatory response [12],
whereas activation of A1R on cells from the monocytes/
macrophage lineage inhibits the production of several pro-
inflammatory cytokines (TNF, IL-8, and IL-6) and enhances
the release of the anti-inflammatory cytokine IL-10, display-
ing an anti-inflammatory response [13, 14]. Therefore,
each receptor can be either beneficially and/or detrimen-
tally implicated in the inflammatory process of COPD.
In this study, our primary aim was to investigate whether
adenosine-related effector mechanisms could be involved in
the persistence and/or progression of the inflammatory
response in COPD following 1-year smoking cessation.
Therefore, adenosine content and receptor expression in
sputum (macrophages and neutrophils) and bronchial
biopsies of smokers with COPD and asymptomatic smokers
were measured, both before and after 1-year smoking
cessation. Since activation of adenosine receptors can
influence the secretion of mediators from inflammatory
cells, we related changes in adenosine and its receptors
with changes in growth factors (VEGF) and chemokines
(monocyte chemoattractant protein (MCP)-1) related to
remodeling and inflammation that may underlie lung
function loss in COPD.
Materials and methods
Subjects
Bronchial biopsy and sputum material of 11 COPD and 15
asymptomatic smoking subjects who successfully stopped
smoking for at least 1 year from the study of Willemse et al.
were studied (patient characteristics; Table 1) [5, 4, 15]. In
short, the main important inclusion and exclusion criteria
for both groups were: COPD (according to the American
Thoracic Society (ATS)/ European Respiratory Society
(ERS) guidelines [16]): forced expiratory volume (FEV)1/
forced vital capacity post-bronchodilator <0.7, and chronic
respiratory symptoms for at least 3 months for two
successive years. Asymptomatic smokers: FEV1≥85%,
predicted, and no chronic respiratory symptoms or airway
obstruction. Participants in both groups were between 45
and 65 years of age, had >10 packyears smoking, smoked
≥10 cigarettes/day, had reversibility to salbutamol <9% of
the predicted FEV1, did not use inhaled or oral cortico-
steroids in the previous 6 months, had no signs of atopy,
and no respiratory tract infections 1 month prior to the
study. During the study, COPD patients only used beta2-
agonists or ipratropium on a regular basis; inhaled cortico-
steroids were not used. Only in case of an exacerbation, a
short course of oral corticosteroids was allowed. Before
each measurement, subjects were asked not to use long- or
short-acting β2-agonists and/or ipratropium at least 12 h
before the test. They did not suffer from a respiratory tract
infection nor used oral corticosteroids in the month prior to
any of the measurements.
The local medical ethics committee of our University
Medical Center Groningen approved the study protocol and
all subjects gave their written informed consent.
Study design and smoking cessation program
The study design and smoking cessation program have
been described previously [5]. Sputum cells and superna-
tant as well as bronchial biopsies were only used if present
both before and after 1-year smoking cessation.
Bronchoscopy and biopsy processing
Bronchial biopsies were taken from the subcarinae of the
right, middle, or lower lobe and processed as described
previously [17]. For immunostaining, sections (one per
patient) were dried and fixed in acetone for 10 min and
washed with phosphate-buffered saline (PBS). The follow-
ing polyclonal antibodies were used: rabbit anti-rat adeno-
sine A1 receptor, rabbit anti-canine adenosine A2A receptor,
rabbit anti-human adenosine A2B receptor (all from Alpha
Diagnostic International, San Antonio, TX, USA), and
rabbit anti-human adenosine A3 receptor (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Antibodies directed
against adenosine A1 and A2A receptors cross-reacted
with human A1R and A2aR. The secondary antibody used
was goat anti-rabbit biotin conjugated (SBA, Birmingham,
AL, USA) and the tertiary antibody StreptABComplex
peroxidase conjugated (DAKO, Glostrup, Denmark). As
chromogen, 3-amino-9-ethyl-carbazol substrate was used;
tissue was counterstained with Mayers’ Hematoxylin.
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Intensity of adenosine receptor expression in biopsies were
scored in a blinded way (all by the same observer) with a
semiquantitative three-point scale, with sections scored as
negative, positive, or strongly positive. In addition, the
total number of positive single cells in the biopsy was
counted. Since not all biopsies presented all tissue structures
scored, numbers presented can vary between graphs.
Sputum induction and processing
Sputum was induced by inhalation of hypertonic saline and
processed as described previously [18]. Sputum samples
consisting for >80% of squamous cells were excluded from
analysis. Cytospins were dried and fixed in acetone for
10 min and washed with PBS for immunostaining. The
same antibodies and chromogen substrate were used as
described in the biopsy staining. Three hundred neutrophilic
granulocytes and 300 macrophages were counted in every
cytospin and scored as negative or positive; the percentage of
cells expressing adenosine receptors was calculated. Due to
the small numbers of lymphocytes present in sputum, we
could not reliably quantify adenosine receptor expression on
this cell type.
Measurement of adenosine in sputum supernatant
using HPLC
Adenosine was measured using a Waters 2690 Alliance
Separation Module HPLC system (Waters, Milford, MA,
USA) coupled on-line to a Finnigan TSQ Quantum Triple
Quadruple Mass Spectrometer (Finnigan Thermo Fisher
Scientific, Waltham, MA, USA). Chromatographic separa-
tion was performed with a C18, 3 μm, Atlantis column
(Waters) 2.1 mm I.D.×100 mm length using a gradient of
mobile phase A (ammonium acetate 20 mM, pH 7.0, in
water) and B (ammonium acetate 20 mM, pH 7.0, in
acetonitrile) at 0.2 mL/min flow rate. Before measurements
samples were pre-treated as follows: 100 μl of sputum
supernatant was acidified with 20 μl of HCl 120 mM,
then 200 μl of chloroform was added to precipitate
proteins and eliminate lipids. After vortexing and subse-
quent centrifugation, 80 μl of the aqueous supernatant
was transferred to a glass injection vial and 5 μl of this
solution was injected into the high-performance liquid
chromatography (HPLC)-mass spectrometry (MS) system.
MS detection was performed using ESI ionization in
positive ion mode. Multiple-reaction monitoring mode
was used to increase the sensitivity. Adenosine was
quantified using the transition m/z 260>m/z 136 corre-
sponding to the loss of the ribofuranose ring. Samples
were measured in a randomized way, twice independently
at two different days. Results were in good agreement
within a maximum of 10% variation. The calibration line
consisted of eight points in the range of 5 to 1,000 ng/ml
adenosine in a mixture of PBS and water (pretreated in the
same way as the study samples). Adenosine levels are
presented as concentrations.
Chemokine and growth factor measurement in sputum
supernatant using multiplex ELISA
Sputum supernatant contents (sensitivity level) of monocyte
chemoattractant protein (MCP)-1 (10 pg/ml), “regulated
upon activation of normal T cell expressed and secreted”
(RANTES, 15 pg/ml), tumor necrosis factor (TNF, 10 pg/ml),
epidermal growth factor (EGF, 15 pg/ml), fibroblast growth
factor (FGF)-basic (also known as FGF2, 15 pg/ml), vascular
endothelial growth factor (VEGF, 15 pg/ml), and platelet-
derived growth factor (PDGF)-BB (<10 pg/ml) were
measured using a human custom multiplex antibody bead
Table 1 Patient characteristics
COPD Asymptomatic smokers
Baseline 1-year SC Baseline 1-year SC
Subjects, n 11 15
Age, years 57 (46–63) 50 (45–57)*
Sex (male/female) 7/4 7/8
Packyears smoking 30 (15–66) 23 (13–32)*
Cigarettes, n/day 20 (10–40) 20 (12–30)
FEV1 post BD, % pred 75.6 (44.4–100.4) 78.1 (49.4–106)** 109.6 (95.5–134.1)* 110.0 (90.0–133.1)
FEV1/VC post BD, % 58.1 (30.1–69.5) 57.5 (36.8–76.2) 78.8 (71.8–88.7)* 79.7 (68.9–92.3)
PC20 Mch, mg/ml 1.02 (0.25–78.4) 13.4 (0.13–78.4)** 33.4 (4.3–78.4)* 78.4 (1.8–78.4)
PC20 AMP, mg/ml 46.2 (4.5–640) 640 (1.04–640)** 640 (73.9–640)* 640 (20–640)***
Data are presented as median (range)
1-year SC 1-year of smoking cessation, FEV1 forced expiratory volume in one second, VC vital capacity, post BD after 400 μg bronchodilator
(salbutamol), % pred percentage of predicted value, Mch Methacholine, AMP adenosine 5′-monophospate
*p<0.05 vs. COPD; **p<0.05 vs. baseline; ***p<0.05 change in COPD versus change in asymptomatic smokers (delta’s)
Virchows Arch (2009) 454:273–281 275
kit from Biosource International (Camarillo, CA, USA).
Standard solutions were diluted with sputolysin reagent
(Calbiochem®, Darmstadt, Germany) to copy the effect of
it on sputum content during processing.
Statistical analysis
Statistics were performed using a Wilcoxon signed-rank test
to assess differences between both measurements within the
groups and a non-parametric Mann–Whitney U test to
assess differences between both groups at baseline. A value
of p<0.05 was considered significant. Correlations between
parameters were investigated using a Pearson’s Rho test.
For some patients material at one time point was missing
due to insufficient quality of the sample. At baseline the
single measurements were used for baseline differences
between both groups, but they were excluded from the
paired test to obtain differences within the groups.
Results
Adenosine receptor expression in bronchial biopsies
The adenosine receptors A2A, A2B, and A3 were expressed
by airway epithelial, endothelial, and smooth muscle cells
in airway wall biopsies and by cells (morphologically
macrophages) in the submucosa in both COPD and
asymptomatic smokers (Fig. 1). In contrast, the A1 receptor
was only expressed on a small number of cells (morpho-
logically macrophages) in the tissue surrounding the
airways. The pattern of expression of the four ARs was
not different between COPD patients and their controls.
The intensity of AR expression (scored semiquantita-
tively with immunohistochemistry) is presented in Fig. 2.
There was no significant difference in AR expression between
both groups at baseline. The A2A receptor expression on
airway smooth muscle decreased significantly after 1-year
smoking cessation (p=0.025) in asymptomatic smokers, but
not in COPD. A1R, A2BR, and A3R expression did not
change with smoking cessation in both groups. In addition,
no differences were found in the number of cells staining
positive for all four ARs between the different groups. Total
biopsy areas were similar for high and low numbers of
positive cells.
Adenosine receptor expression by sputum cells
In sputum, all four ARs were expressed by neutrophils
and macrophages of both COPD and asymptomatic
smokers. There was no difference in AR expression
between both groups at baseline. The percentage of A3R
positive neutrophils increased significantly in COPD
patients after 1-year smoking cessation when compared to
baseline (p=0.038). This change in A3R expression was
significantly different from the change occurring in
asymptomatic smokers (p=0.050, Fig. 3a). No changes
were detected in percentages of neutrophils expressing
A1R, A2AR, and A2BR. In COPD patients, the percentage
of A1R positive macrophages increased after 1-year
smoking cessation when compared to baseline (p=0.017,
Fig. 3b), an effect that was not observed in asymptomatic
smokers. Smoking cessation had no effect on expression
of the other ARs on macrophages. No significant differ-
ences were found in percentage expression of all ARs on
macrophages between COPD and asymptomatic smokers.
Adenosine, growth factors, and cytokine levels in sputum
supernatant
Adenosine levels in sputum supernatant were significantly
lower in COPD at baseline (p=0.017, Fig. 4a) than in
asymptomatic smokers, whereas VEGF levels were higher
(p=0.020, Fig. 4b). In addition, the change in adenosine
levels with smoking cessation was significantly different in
COPD and asymptomatic smokers (p=0.023), as was the
change in MCP-1 (p=0.013) (Fig. 4). No differences were
detected in RANTES and other growth factors involved in
tissue repair (EGF and PDGF-BB) (Fig. 4). Levels of FGF-
b and TNF were below the sensitivity level and therefore
not analyzed statistically.
Discussion
We investigated the effect of smoking cessation on
adenosine content and adenosine receptor expression in
sputum and biopsies taken from COPD patients and
asymptomatic smokers. Our most important observations
were that COPD patients responded significantly different
to smoking cessation than asymptomatic smokers with
respect to sputum adenosine content, MCP-1 levels, and
percentage of neutrophils expressing A3R and macrophages
expressing A1R. This resulted in an increased adenosine
content (trend) and increased percentage of A3R positive
neutrophils and A1R positive macrophages in sputum of
COPD patients. In addition, smokers with COPD have a
lower level of adenosine and a higher level of VEGF in
sputum than asymptomatic smokers.
Previous observations in these patients have elucidated
that smoking cessation improved AHR, whereas inflamma-
tion persisted or even increased in sputum of COPD
patients [4, 5]. Since adenosine is implicated in the
development and persistence of inflammation, we investi-
gated in the current study whether the observed increase in
(aspects of) inflammation in COPD could be explained by
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the presence of adenosine and the expression of adenosine
receptors as measured in two different compartments of the
airways, i.e. sputum and bronchial biopsies.
We confirmed the pattern of ARs expression that was
recently described by Varani et al. [10]. Thus, the A2AR and
A3R were expressed on bronchial epithelium, smooth
muscle cells, endothelial cells, and infiltrating cells (mostly
macrophages), whereas A1R was only expressed by a few
cells (morphologically macrophages). For A2BR, Varani
and co-workers detected expression on mast cells and
macrophages only, whereas we additionally detected expres-
sion on epithelium, smooth muscle and endothelial cells,
using the same antibody. With respect to the intensity of AR
expression, no differences were found between COPD and
asymptomatic smokers in our study. Interestingly, Varani
et al. detected an increased expression of A2AR and A3R
Fig. 1 Adenosine receptor ex-
pression on bronchial biopsies
from smoking asymptomatic
(left panel) and COPD (right
panel) subjects
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at the mRNA level, a decreased expression of A2BR and
no differences for A1R mRNA in airway wall tissue of
COPD patients. We did not study mRNA expression of AR.
Other differences between both studies may be explained
by differences in the clinical characteristics of the investi-
gated participants. At baseline, we investigated current
smokers, whereas both the COPD and healthy smoking
groups of Varani et al. consisted of a mixture of ex- and
current smokers. Our data on the effects of 1-year smoking
cessation show that this may have affected the results of the
latter study. Also, some of the participants of Varani et al.
were older and had higher packyears of smoking.
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Fig. 2 Semi-quantitative scoring of the immunohistochemical stain-
ing of adenosine receptor expression on bronchial biopsies from
smoking asymptomatic (AS) and COPD subjects, before and 1-year
after smoking cessation. Structures present in bronchial biopsies were
scored negative, positive, or strongly positive. Significant differences
are depicted in the graphs. Paired data for 11 asymptomatic smokers
and ten COPD patients
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Fig. 3 Adenosine receptor expression on neutrophils (a) and macro-
phages (b) in sputum of COPD patients and asymptomatic smokers
(AS), before and after 1-year smoking cessation. Significant differ-
ences are depicted in the graphs. Paired data for 11 asymptomatic
smokers and ten COPD patients
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We report for the first time the expression of all four
adenosine receptors on neutrophils and macrophages in
sputum of COPD and asymptomatic smokers. At baseline,
no differences were found between asymptomatic smokers
and COPD patients. With respect to neutrophils, smoking
cessation resulted in a significantly higher percentage of
sputum neutrophils expressing A3R on their membrane in
COPD, an effect not observed in asymptomatic smokers.
The role of the human adenosine A3 receptor is poorly
understood. mRNA for the adenosine A3 receptor is highest
in the central nervous system, liver, and lung [19, 20]. A
recent study showed that a ligand which combines adenosine
A2A receptor agonist and A3 receptor antagonist activity
inhibits the release of preformed granule proteins from
neutrophils [21]. Another recent study showed that the A3R
on neutrophils is additionally involved in neutrophilic
chemotaxis [22]. This is of interest since we previously
showed that the number of sputum neutrophils significantly
increased in COPD patients who successfully quitted
smoking for 1 year. The role of these neutrophils is still
not clear but theoretically they could contribute to the
enhanced adenosine levels after smoking cessation in COPD.
The exact contribution of adenosine in the persistence and
progression of the inflammatory response is further dictated
by the expression pattern of the four different adenosine
receptors.
The percentage of macrophages expressing the A1R was
increased in COPD patients after 1-year of smoking
cessation. Recently, a role for the A1R on monocytes was
described in modulation of angiogenesis [23]. The A1R-
selective agonist N6-cyclopenthyladenosine increased
VEGF production by human monocytes in vitro and
increased angiogenesis in a chicken chorioallantoic mem-
brane model. In the present study, levels of chemokines and
various growth factors were measured in sputum superna-
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Fig. 4 Sputum adenosine (a),
VEGF (b), EGF (c), PDGF-BB
(d), MCP-1 (e), and RANTES
(f) levels of CODP patients and
asymptomatic smokers (AS),
before and after 1-year smoking
cessation. * Significant differ-
ence at baseline (p<0.05) be-
tween COPD and AS, other
significant differences are
depicted in the graphs. Paired
data for nine asymptomatic
smokers and seven COPD
patients
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mechanism in the airways. Smoking cessation had a
differential effect on MCP-1 production in sputum super-
natant when comparing COPD with asymptomatic smokers.
Since this chemokine is involved in recruitment of macro-
phages, the observed relative increase in MCP-1 in COPD
with smoking cessation compared to asymptomatic indi-
viduals is in line with the previously published observation
that the number of macrophages decreases upon smoking
cessation in asymptomatic smokers, whereas it persists in
COPD [5]. RANTES levels were similar in both groups and
smoking cessation did not alter this. RANTES increases
during COPD exacerbations [24] and is involved in
chemotaxis of eosinophils. The percentage of eosinophils
decreased in both COPD and asymptomatic patients after
smoking cessation [5]. This thus could not be explained by
RANTES. We found that COPD patients had higher levels
of VEGF in sputum than asymptomatic smokers, compat-
ible with findings described by Rovina et al. [25] and other
research groups describing higher VEGF levels in sputum
of patients suffering from chronic bronchitis and lower levels
in patients with emphysema [25–27]. Cigarette smoking may
upregulate VEGF, as suggested by an acute increase of
VEGF plasma levels during smoking [28], yet we here show
that smoking cessation did not reduce VEGF levels in both
our groups.
Finally, we observed that smoking cessation decreased
levels of adenosine in asymptomatic smokers, whereas it
increased (trend) adenosine levels in COPD patients. This is
of interest and in line with the observation that a number of
inflammation markers significantly decreased in asymptom-
atic smokers who successfully quitted smoking while the
number of sputum neutrophils, lymphocytes, interleukin-8,
and eosinophil-cationic-protein levels significantly in-
creased in COPD patients who successfully ceased smoking
for 1 year [5].
Conclusions
We have shown that COPD patients respond significantly
different to smoking cessation than asymptomatic smokers
with respect to adenosine production and adenosine receptor
expression. Our results may indicate that adenosine-related
effector mechanisms are involved in the persistence and
progression of the inflammatory response in COPD follow-
ing 1-year smoking cessation.
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